DeepMed Research

Abbisko Therapeutics Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Mass Balance Study of [14C]ABSK011

Phase 1

Not yet recruiting

Conditions: Healthy Subjects

Interventions: Drug: [14C]ABSK011

First Posted Date: 2025-03-26

Last Posted Date: 2025-03-26

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 6

Registration Number: NCT06896760

Locations: 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China

A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Healthy Subjects

Interventions: Drug: Pimicotinib capsule

First Posted Date: 2025-03-19

Last Posted Date: 2025-04-20

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 16

Registration Number: NCT06884072

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

A Study to Investigate the Effect of Pimicotinib on the Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Healthy Subjects

Interventions: Drug: pimicotinib capsules

First Posted Date: 2025-01-16

Last Posted Date: 2025-03-20

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 38

Registration Number: NCT06779253

Locations: 🇨🇳
The First Affiliated Hospital Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China

A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: pimicotinib capsules

First Posted Date: 2024-11-19

Last Posted Date: 2025-02-17

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 26

Registration Number: NCT06694948

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer With EGFR Mutation

Interventions: Drug: ABSK043 in combination with Firmonertinib

First Posted Date: 2024-10-31

Last Posted Date: 2024-12-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 54

Registration Number: NCT06668103

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Union Hospital Tongji Medical College Huzhong University of Science and Techology, Wuhan, Hubei, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

and more 2 locations

A Phase 2 Clinical Study of ABSK061 and ABSK043

Phase 2

Recruiting

Conditions: HER2-Gastric/Gastroesophageal Junction Cancer
Urothelial Carcinoma
Non-Small Cell Lung Cancer
Solid Tumors

Interventions: Drug: ABSK061+ABSK043 in combination with CAPOX
Drug: ABSK061 + ABSK043

First Posted Date: 2024-10-09

Last Posted Date: 2024-11-19

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 202

Registration Number: NCT06632262

Locations: 🇨🇳
Guizhou Provincial People'S Hospital, Guiyang, Guizhou, China
🇨🇳
The Affiliated Hospital of Guizhou Medical University, GuiYang, Guizhou, China
🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Heibei, China

and more 18 locations

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Pimicotinib

First Posted Date: 2024-08-20

Last Posted Date: 2025-03-25

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 24

Registration Number: NCT06562946

Locations: 🇨🇳
The first hospital of Jilin University, Changchun, Jilin, China

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ABSK021
Drug: Omeprazole

First Posted Date: 2024-03-21

Last Posted Date: 2025-02-18

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 36

Registration Number: NCT06322706

Locations: 🇨🇳
Wuxi People's Hospital, Wuxi, JiangShu, China

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

Phase 1

Recruiting

Conditions: Healthy Subjects

Interventions: Drug: Sequence A ABSK-011
Drug: Sequence B ABSK-011

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 73

Registration Number: NCT06306872

Locations: 🇨🇳
Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: ABSK112

First Posted Date: 2024-01-26

Last Posted Date: 2024-03-18

Lead Sponsor: Abbisko Therapeutics Co, Ltd

Target Recruit Count: 164

Registration Number: NCT06225804

Locations: 🇨🇳
The first Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Harbin, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy